4//SEC Filing
Stoppel Laura 4
Accession 0001576885-25-000084
CIK 0001576885other
Filed
Jun 4, 8:00 PM ET
Accepted
Jun 5, 6:05 PM ET
Size
8.1 KB
Accession
0001576885-25-000084
Insider Transaction Report
Form 4
Stoppel Laura
Director
Transactions
- Award
Stock Option (right to buy)
2025-06-04+19,500→ 19,500 totalExercise: $1.07Exp: 2035-06-04→ Common Stock (19,500 underlying) - Award
Common Stock
2025-06-04+12,800→ 12,800 total
Footnotes (3)
- [F1]Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option and RSUs for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), R.A. Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement, as applicable, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.
- [F3]The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Documents
Issuer
Acumen Pharmaceuticals, Inc.
CIK 0001576885
Entity typeother
Related Parties
1- filerCIK 0001865119
Filing Metadata
- Form type
- 4
- Filed
- Jun 4, 8:00 PM ET
- Accepted
- Jun 5, 6:05 PM ET
- Size
- 8.1 KB